Next Article in Journal
Dichloromethane Extracts of Geranium Koreanum Kom. Alleviates Esophagus Damage in Acute Reflux Esophagitis-Induced Rats by Anti-Inflammatory Activities
Next Article in Special Issue
Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update
Previous Article in Journal
Transfection of T-Box Transcription Factor BRACHYURY and SOX2 Synergistically Promote Self-Renewal and Invasive Phenotype in Oral Cancer Cells
Previous Article in Special Issue
Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma
Open AccessReview

Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma

1
Department of Internal Medicine, Hematology, Oncology, and Bone Marrow Transplant Division, University of Iowa, Iowa City, IA 52242, USA
2
Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA
3
Graduate Program in Molecular Medicine, University of Iowa, Iowa City, IA 52242, USA
4
Department of Health Human Physiology, University of Iowa, Iowa City, IA 52242, USA
5
Stead Family Department of Pediatrics, University of Iowa, Iowa, IA 52242, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(11), 3621; https://doi.org/10.3390/ijms19113621
Received: 28 September 2018 / Revised: 6 November 2018 / Accepted: 13 November 2018 / Published: 16 November 2018
(This article belongs to the Special Issue Novel Therapeutic Strategies in Multiple Myeloma)
Multiple myeloma is an invariably fatal cancer of plasma cells. Despite tremendous advances in treatment, this malignancy remains incurable in most individuals. We postulate that strategies aimed at prevention have the potential to be more effective in preventing myeloma-related death than additional pharmaceutical strategies aimed at treating advanced disease. Here, we present a rationale for the development of prevention therapy and highlight potential target areas of study. View Full-Text
Keywords: multiple myeloma; prevention; monoclonal gammopathy of undetermined significance; plasma cell disease; therapy multiple myeloma; prevention; monoclonal gammopathy of undetermined significance; plasma cell disease; therapy
Show Figures

Graphical abstract

MDPI and ACS Style

Tomasson, M.H.; Ali, M.; De Oliveira, V.; Xiao, Q.; Jethava, Y.; Zhan, F.; Fitzsimmons, A.M.; Bates, M.L. Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma. Int. J. Mol. Sci. 2018, 19, 3621.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop